http://www.biocentury.com/rss/weekinreviewWeek in Reviewen-US Copyright 2013 BioCentury, Inc.RSS Generatorhttp://www.biocentury.com/Data/NewsCenter2/Images/WeekInReview/Coverstory.gifhttp://www.biocentury.com/rss/weekinreviewhttp://www.biocentury.com/weekinreview/deals/2013-05-13/acceleron-shire-deal-318456http://www.biocentury.com/weekinreview/deals/2013-05-13/acceleron-shire-deal-318456DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/afraxis-servier-deal-318457http://www.biocentury.com/weekinreview/deals/2013-05-13/afraxis-servier-deal-318457DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/albion-medical-holdings-inc-ares-life-sciences-deal-318458http://www.biocentury.com/weekinreview/deals/2013-05-13/albion-medical-holdings-inc-ares-life-sciences-deal-318458DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/alexza-teva-deal-318459http://www.biocentury.com/weekinreview/deals/2013-05-13/alexza-teva-deal-318459DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/allegro-ophthalmics-senju-deal-318460http://www.biocentury.com/weekinreview/deals/2013-05-13/allegro-ophthalmics-senju-deal-318460DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/amgen-transgenomic-deal-318461http://www.biocentury.com/weekinreview/deals/2013-05-13/amgen-transgenomic-deal-318461DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/batavia-bioservices-bv-university-of-amsterdam-deal-318462http://www.biocentury.com/weekinreview/deals/2013-05-13/batavia-bioservices-bv-university-of-amsterdam-deal-318462DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/biohelix-quidel-deal-318464http://www.biocentury.com/weekinreview/deals/2013-05-13/biohelix-quidel-deal-318464DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/bio-matrix-scientific-university-of-western-ontario-deal-318463http://www.biocentury.com/weekinreview/deals/2013-05-13/bio-matrix-scientific-university-of-western-ontario-deal-318463DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/bioview-kindstar-global-co-ltd-deal-318465http://www.biocentury.com/weekinreview/deals/2013-05-13/bioview-kindstar-global-co-ltd-deal-318465DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/bracco-diagnostics-emergent-biosolutions-deal-318466http://www.biocentury.com/weekinreview/deals/2013-05-13/bracco-diagnostics-emergent-biosolutions-deal-318466DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/celgene-concert-pharmaceuticals-deal-318467http://www.biocentury.com/weekinreview/deals/2013-05-13/celgene-concert-pharmaceuticals-deal-318467DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/cellmid-advangen-inc-deal-318468http://www.biocentury.com/weekinreview/deals/2013-05-13/cellmid-advangen-inc-deal-318468DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/co-diagnostics-inc-dna-logix-inc-deal-318469http://www.biocentury.com/weekinreview/deals/2013-05-13/co-diagnostics-inc-dna-logix-inc-deal-318469DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/conceptus-bayer-deal-318470http://www.biocentury.com/weekinreview/deals/2013-05-13/conceptus-bayer-deal-318470DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/constellation-diagnostics-tauriga-sciences-deal-318471http://www.biocentury.com/weekinreview/deals/2013-05-13/constellation-diagnostics-tauriga-sciences-deal-318471DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/debiopharm-oncotest-gmbh-deal-318472http://www.biocentury.com/weekinreview/deals/2013-05-13/debiopharm-oncotest-gmbh-deal-318472DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/drais-tacurion-astellas-deal-318473http://www.biocentury.com/weekinreview/deals/2013-05-13/drais-tacurion-astellas-deal-318473DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/foundation-medicine-memorial-sloan-kettering-cancer-center-deal-318474http://www.biocentury.com/weekinreview/deals/2013-05-13/foundation-medicine-memorial-sloan-kettering-cancer-center-deal-318474DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/full-spectrum-genetics-deal-318475http://www.biocentury.com/weekinreview/deals/2013-05-13/full-spectrum-genetics-deal-318475DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/glide-pharma-pfenex-deal-318476http://www.biocentury.com/weekinreview/deals/2013-05-13/glide-pharma-pfenex-deal-318476DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/hyperion-valeant-pharmaceuticals-deal-318477http://www.biocentury.com/weekinreview/deals/2013-05-13/hyperion-valeant-pharmaceuticals-deal-318477DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/ilika-plc-regenerys-ltd-deal-318478http://www.biocentury.com/weekinreview/deals/2013-05-13/ilika-plc-regenerys-ltd-deal-318478DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/inverclyde-biologicals-ltd-source-bioscience-plc-deal-318479http://www.biocentury.com/weekinreview/deals/2013-05-13/inverclyde-biologicals-ltd-source-bioscience-plc-deal-318479DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/inviragen-takeda-deal-318480http://www.biocentury.com/weekinreview/deals/2013-05-13/inviragen-takeda-deal-318480DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/jandj-scripps-research-institute-deal-318481http://www.biocentury.com/weekinreview/deals/2013-05-13/jandj-scripps-research-institute-deal-318481DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/kinex-pharmaceuticals-zenith-technology-corp-deal-318482http://www.biocentury.com/weekinreview/deals/2013-05-13/kinex-pharmaceuticals-zenith-technology-corp-deal-318482DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/ligand-selexis-deal-318483http://www.biocentury.com/weekinreview/deals/2013-05-13/ligand-selexis-deal-318483DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/morphosys-novartis-deal-318484http://www.biocentury.com/weekinreview/deals/2013-05-13/morphosys-novartis-deal-318484DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/nimbus-discovery-shire-deal-318485http://www.biocentury.com/weekinreview/deals/2013-05-13/nimbus-discovery-shire-deal-318485DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/ocera-tranzyme-deal-318486http://www.biocentury.com/weekinreview/deals/2013-05-13/ocera-tranzyme-deal-318486DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/oncobiologics-huahai-deal-318487http://www.biocentury.com/weekinreview/deals/2013-05-13/oncobiologics-huahai-deal-318487DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/oxford-biomedica-novartis-deal-318488http://www.biocentury.com/weekinreview/deals/2013-05-13/oxford-biomedica-novartis-deal-318488DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/pharmascience-redx-pharma-deal-318489http://www.biocentury.com/weekinreview/deals/2013-05-13/pharmascience-redx-pharma-deal-318489DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/protein-sciences-deal-318490http://www.biocentury.com/weekinreview/deals/2013-05-13/protein-sciences-deal-318490DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/raptor-aix-marseille-university-french-national-institute-of-health-and-medical-research-(inserm)-318491http://www.biocentury.com/weekinreview/deals/2013-05-13/raptor-aix-marseille-university-french-national-institute-of-health-and-medical-research-(inserm)-318491DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/sagent-pharmaceuticals-chengdu-kanghong-pharmaceuticals-co-ltd-deal-318492http://www.biocentury.com/weekinreview/deals/2013-05-13/sagent-pharmaceuticals-chengdu-kanghong-pharmaceuticals-co-ltd-deal-318492DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/sanofi-chemrar-ventures-deal-318493http://www.biocentury.com/weekinreview/deals/2013-05-13/sanofi-chemrar-ventures-deal-318493DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/trevena-forest-laboratories-deal-318494http://www.biocentury.com/weekinreview/deals/2013-05-13/trevena-forest-laboratories-deal-318494DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2013-05-13/warner-chilcott-actavis-deal-318495http://www.biocentury.com/weekinreview/deals/2013-05-13/warner-chilcott-actavis-deal-318495DealsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2013-05-13/alimera-sciences-psivida-sales-and-marketing-update-318558http://www.biocentury.com/weekinreview/salesmarketing/2013-05-13/alimera-sciences-psivida-sales-and-marketing-update-318558Sales and MarketingMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2013-05-13/biotie-lundbeck-sales-and-marketing-update-318559http://www.biocentury.com/weekinreview/salesmarketing/2013-05-13/biotie-lundbeck-sales-and-marketing-update-318559Sales and MarketingMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2013-05-13/cancer-genetics-sales-and-marketing-update-318560http://www.biocentury.com/weekinreview/salesmarketing/2013-05-13/cancer-genetics-sales-and-marketing-update-318560Sales and MarketingMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2013-05-13/concordia-shionogi-sales-and-marketing-update-318561http://www.biocentury.com/weekinreview/salesmarketing/2013-05-13/concordia-shionogi-sales-and-marketing-update-318561Sales and MarketingMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2013-05-13/cornerstone-therapeutics-digestive-care-sales-and-marketing-update-318562http://www.biocentury.com/weekinreview/salesmarketing/2013-05-13/cornerstone-therapeutics-digestive-care-sales-and-marketing-update-318562Sales and MarketingMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2013-05-13/dainippon-sumitomo-ono-pharmaceutical-sales-and-marketing-update-318563http://www.biocentury.com/weekinreview/salesmarketing/2013-05-13/dainippon-sumitomo-ono-pharmaceutical-sales-and-marketing-update-318563Sales and MarketingMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2013-05-13/genomic-health-sales-and-marketing-update-318564http://www.biocentury.com/weekinreview/salesmarketing/2013-05-13/genomic-health-sales-and-marketing-update-318564Sales and MarketingMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2013-05-13/intas-pharmaceuticals-sales-and-marketing-update-318565http://www.biocentury.com/weekinreview/salesmarketing/2013-05-13/intas-pharmaceuticals-sales-and-marketing-update-318565Sales and MarketingMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2013-05-13/martindale-pharma-sales-and-marketing-update-318566http://www.biocentury.com/weekinreview/salesmarketing/2013-05-13/martindale-pharma-sales-and-marketing-update-318566Sales and MarketingMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2013-05-13/paladin-pernix-therapeutics-sales-and-marketing-update-318567http://www.biocentury.com/weekinreview/salesmarketing/2013-05-13/paladin-pernix-therapeutics-sales-and-marketing-update-318567Sales and MarketingMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2013-05-13/shionogi-sales-and-marketing-update-318568http://www.biocentury.com/weekinreview/salesmarketing/2013-05-13/shionogi-sales-and-marketing-update-318568Sales and MarketingMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2013-05-13/ap-pharma-management-update-318387http://www.biocentury.com/weekinreview/management/2013-05-13/ap-pharma-management-update-318387ManagementMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2013-05-13/advaxis-management-update-318388http://www.biocentury.com/weekinreview/management/2013-05-13/advaxis-management-update-318388ManagementMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2013-05-13/bg-medicine-management-update-318389http://www.biocentury.com/weekinreview/management/2013-05-13/bg-medicine-management-update-318389ManagementMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2013-05-13/cepheid-management-update-318390http://www.biocentury.com/weekinreview/management/2013-05-13/cepheid-management-update-318390ManagementMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2013-05-13/dyadic-international-management-update-318391http://www.biocentury.com/weekinreview/management/2013-05-13/dyadic-international-management-update-318391ManagementMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2013-05-13/eli-lilly-management-update-318392http://www.biocentury.com/weekinreview/management/2013-05-13/eli-lilly-management-update-318392ManagementMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2013-05-13/retrophin-management-update-318393http://www.biocentury.com/weekinreview/management/2013-05-13/retrophin-management-update-318393ManagementMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-05-13/abbvie-boehringer-ingelheim-eli-lilly-glaxosmithkline-jandj-novartis-pfizer-takeda-pharmaceutic-318569http://www.biocentury.com/weekinreview/othercompany/2013-05-13/abbvie-boehringer-ingelheim-eli-lilly-glaxosmithkline-jandj-novartis-pfizer-takeda-pharmaceutic-318569Other NewsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-05-13/affymax-hematology-news-318570http://www.biocentury.com/weekinreview/othercompany/2013-05-13/affymax-hematology-news-318570Other NewsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-05-13/astrazeneca-neurology-news-318571http://www.biocentury.com/weekinreview/othercompany/2013-05-13/astrazeneca-neurology-news-318571Other NewsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-05-13/cellectis-precision-biosciences-genomics-news-318572http://www.biocentury.com/weekinreview/othercompany/2013-05-13/cellectis-precision-biosciences-genomics-news-318572Other NewsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-05-13/chrontech-infectious-drug-delivery-news-318573http://www.biocentury.com/weekinreview/othercompany/2013-05-13/chrontech-infectious-drug-delivery-news-318573Other NewsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-05-13/glaxosmithkline-other-news-318574http://www.biocentury.com/weekinreview/othercompany/2013-05-13/glaxosmithkline-other-news-318574Other NewsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-05-13/glaxosmithkline-merck-global-alliance-for-vaccine-immunization-(gavi)-infectious-news-318576http://www.biocentury.com/weekinreview/othercompany/2013-05-13/glaxosmithkline-merck-global-alliance-for-vaccine-immunization-(gavi)-infectious-news-318576Other NewsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-05-13/glaxosmithkline-the-wellcome-trust-infectious-news-318575http://www.biocentury.com/weekinreview/othercompany/2013-05-13/glaxosmithkline-the-wellcome-trust-infectious-news-318575Other NewsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-05-13/liquidia-ophthalmic-news-318577http://www.biocentury.com/weekinreview/othercompany/2013-05-13/liquidia-ophthalmic-news-318577Other NewsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-05-13/pfizer-alberta-innovations---health-solutions-pharmaceuticals-news-318578http://www.biocentury.com/weekinreview/othercompany/2013-05-13/pfizer-alberta-innovations---health-solutions-pharmaceuticals-news-318578Other NewsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-05-13/plandai-infectious-agbioenvironmental-news-318579http://www.biocentury.com/weekinreview/othercompany/2013-05-13/plandai-infectious-agbioenvironmental-news-318579Other NewsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-05-13/redx-pharma-infectious-news-318580http://www.biocentury.com/weekinreview/othercompany/2013-05-13/redx-pharma-infectious-news-318580Other NewsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-05-13/sanofi-pharmaceuticals-news-318581http://www.biocentury.com/weekinreview/othercompany/2013-05-13/sanofi-pharmaceuticals-news-318581Other NewsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-05-13/takeda-pharmaceuticals-news-318582http://www.biocentury.com/weekinreview/othercompany/2013-05-13/takeda-pharmaceuticals-news-318582Other NewsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-05-13/teva-endocrinemetabolic-news-318583http://www.biocentury.com/weekinreview/othercompany/2013-05-13/teva-endocrinemetabolic-news-318583Other NewsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2013-05-13/warnex-supplyservice-news-318584http://www.biocentury.com/weekinreview/othercompany/2013-05-13/warnex-supplyservice-news-318584Other NewsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2013-05-13/eli-lilly-board-of-directors-update-318383http://www.biocentury.com/weekinreview/management/2013-05-13/eli-lilly-board-of-directors-update-318383Boards of DirectorsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2013-05-13/lumena-pharmaceuticals-board-of-directors-update-318384http://www.biocentury.com/weekinreview/management/2013-05-13/lumena-pharmaceuticals-board-of-directors-update-318384Boards of DirectorsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2013-05-13/neurophage-board-of-directors-update-318385http://www.biocentury.com/weekinreview/management/2013-05-13/neurophage-board-of-directors-update-318385Boards of DirectorsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2013-05-13/trevena-board-of-directors-update-318386http://www.biocentury.com/weekinreview/management/2013-05-13/trevena-board-of-directors-update-318386Boards of DirectorsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/abt-267-regulatory-update-318405http://www.biocentury.com/weekinreview/regulatory/2013-05-13/abt-267-regulatory-update-318405RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/actemra-regulatory-update-318411http://www.biocentury.com/weekinreview/regulatory/2013-05-13/actemra-regulatory-update-318411RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/belviq-lorcaserin-regulatory-update-318396http://www.biocentury.com/weekinreview/regulatory/2013-05-13/belviq-lorcaserin-regulatory-update-318396RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/breo-ellipta-regulatory-update-318430http://www.biocentury.com/weekinreview/regulatory/2013-05-13/breo-ellipta-regulatory-update-318430RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/bridion-sugammadex-regulatory-update-318417http://www.biocentury.com/weekinreview/regulatory/2013-05-13/bridion-sugammadex-regulatory-update-318417RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/ceftolozanetazobactam-regulatory-update-318402http://www.biocentury.com/weekinreview/regulatory/2013-05-13/ceftolozanetazobactam-regulatory-update-318402RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/cycloset-bromocriptine-mesylate-regulatory-update-318433http://www.biocentury.com/weekinreview/regulatory/2013-05-13/cycloset-bromocriptine-mesylate-regulatory-update-318433RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/depakote-divalproex-regulatory-update-318406http://www.biocentury.com/weekinreview/regulatory/2013-05-13/depakote-divalproex-regulatory-update-318406RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/dificid-fidaxomicin-regulatory-update-318422http://www.biocentury.com/weekinreview/regulatory/2013-05-13/dificid-fidaxomicin-regulatory-update-318422RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/dynavisc-regulatory-update-318410http://www.biocentury.com/weekinreview/regulatory/2013-05-13/dynavisc-regulatory-update-318410RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/eliquis-apixaban-regulatory-update-318399http://www.biocentury.com/weekinreview/regulatory/2013-05-13/eliquis-apixaban-regulatory-update-318399RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/exjade-deferasirox-regulatory-update-318420http://www.biocentury.com/weekinreview/regulatory/2013-05-13/exjade-deferasirox-regulatory-update-318420RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/ilaris-canakinumab-regulatory-update-318398http://www.biocentury.com/weekinreview/regulatory/2013-05-13/ilaris-canakinumab-regulatory-update-318398RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/incivo-telaprevir-regulatory-update-318434http://www.biocentury.com/weekinreview/regulatory/2013-05-13/incivo-telaprevir-regulatory-update-318434RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/inotuzumab-ozogamicin-regulatory-update-318431http://www.biocentury.com/weekinreview/regulatory/2013-05-13/inotuzumab-ozogamicin-regulatory-update-318431RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/ipi-145-regulatory-update-318414http://www.biocentury.com/weekinreview/regulatory/2013-05-13/ipi-145-regulatory-update-318414RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/juvederm-voluma-xc-regulatory-update-318395http://www.biocentury.com/weekinreview/regulatory/2013-05-13/juvederm-voluma-xc-regulatory-update-318395RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/kadcyla-ado-trastuzumab-emtansine-regulatory-update-318412http://www.biocentury.com/weekinreview/regulatory/2013-05-13/kadcyla-ado-trastuzumab-emtansine-regulatory-update-318412RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/lenvatinib-regulatory-update-318404http://www.biocentury.com/weekinreview/regulatory/2013-05-13/lenvatinib-regulatory-update-318404RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/liptruzet-ezetimibeatorvastatin-regulatory-update-318418http://www.biocentury.com/weekinreview/regulatory/2013-05-13/liptruzet-ezetimibeatorvastatin-regulatory-update-318418RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/luseogliflozin-regulatory-update-318429http://www.biocentury.com/weekinreview/regulatory/2013-05-13/luseogliflozin-regulatory-update-318429RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/maci-regulatory-update-318426http://www.biocentury.com/weekinreview/regulatory/2013-05-13/maci-regulatory-update-318426RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/menveo-regulatory-update-318421http://www.biocentury.com/weekinreview/regulatory/2013-05-13/menveo-regulatory-update-318421RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/octava-pink-regulatory-update-318409http://www.biocentury.com/weekinreview/regulatory/2013-05-13/octava-pink-regulatory-update-318409RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/oxymorphone-regulatory-update-318407http://www.biocentury.com/weekinreview/regulatory/2013-05-13/oxymorphone-regulatory-update-318407RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/pexastimogene-devacirepvec-regulatory-update-318416http://www.biocentury.com/weekinreview/regulatory/2013-05-13/pexastimogene-devacirepvec-regulatory-update-318416RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/potiga-ezogabine-regulatory-update-318432http://www.biocentury.com/weekinreview/regulatory/2013-05-13/potiga-ezogabine-regulatory-update-318432RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/pradaxa-dabigatran-etexilate-regulatory-update-318397http://www.biocentury.com/weekinreview/regulatory/2013-05-13/pradaxa-dabigatran-etexilate-regulatory-update-318397RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/protelos-strontium-ranelate-regulatory-update-318427http://www.biocentury.com/weekinreview/regulatory/2013-05-13/protelos-strontium-ranelate-regulatory-update-318427RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/ragweed-allergy-immunotherapy-tablet-regulatory-update-318394http://www.biocentury.com/weekinreview/regulatory/2013-05-13/ragweed-allergy-immunotherapy-tablet-regulatory-update-318394RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/relasv-antigen-rapid-test-regulatory-update-318401http://www.biocentury.com/weekinreview/regulatory/2013-05-13/relasv-antigen-rapid-test-regulatory-update-318401RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/relistor-methylnaltrexone-regulatory-update-318424http://www.biocentury.com/weekinreview/regulatory/2013-05-13/relistor-methylnaltrexone-regulatory-update-318424RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/remoxy-oxycodone-regulatory-update-318403http://www.biocentury.com/weekinreview/regulatory/2013-05-13/remoxy-oxycodone-regulatory-update-318403RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/revlimid-lenalidomide-regulatory-update-318400http://www.biocentury.com/weekinreview/regulatory/2013-05-13/revlimid-lenalidomide-regulatory-update-318400RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/samsca-tolvaptan-regulatory-update-318423http://www.biocentury.com/weekinreview/regulatory/2013-05-13/samsca-tolvaptan-regulatory-update-318423RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/sativex-regulatory-update-318413http://www.biocentury.com/weekinreview/regulatory/2013-05-13/sativex-regulatory-update-318413RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/sustiva-efavirenz-regulatory-update-318419http://www.biocentury.com/weekinreview/regulatory/2013-05-13/sustiva-efavirenz-regulatory-update-318419RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/tetrazepam-containing-medicines-regulatory-update-318408http://www.biocentury.com/weekinreview/regulatory/2013-05-13/tetrazepam-containing-medicines-regulatory-update-318408RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/trametinib-regulatory-update-318415http://www.biocentury.com/weekinreview/regulatory/2013-05-13/trametinib-regulatory-update-318415RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/uplyso-alfataliglicerase-regulatory-update-318425http://www.biocentury.com/weekinreview/regulatory/2013-05-13/uplyso-alfataliglicerase-regulatory-update-318425RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2013-05-13/vyvanse-lisdexamfetamine-dimesylate-regulatory-update-318428http://www.biocentury.com/weekinreview/regulatory/2013-05-13/vyvanse-lisdexamfetamine-dimesylate-regulatory-update-318428RegulatoryMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/af802-phase-iii-data-318445http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/af802-phase-iii-data-318445Clinical ResultsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/alrn-5281-phase-i-data-318436http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/alrn-5281-phase-i-data-318436Clinical ResultsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/apremilast-phase-iii-data-318443http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/apremilast-phase-iii-data-318443Clinical ResultsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/cmx001-infectious-data-318444http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/cmx001-infectious-data-318444Clinical ResultsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/ebi-005-phase-ia-data-318448http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/ebi-005-phase-ia-data-318448Clinical ResultsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/enzastaurin-development-discontinued-318449http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/enzastaurin-development-discontinued-318449Clinical ResultsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/etc-1002-final-phase-ii-data-318450http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/etc-1002-final-phase-ii-data-318450Clinical ResultsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/faldaprevir-phase-iii-data-318442http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/faldaprevir-phase-iii-data-318442Clinical ResultsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/feraheme-ferumoxytol-additional-phase-iii-data-318455http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/feraheme-ferumoxytol-additional-phase-iii-data-318455Clinical ResultsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/gammagard-liquid-10-phase-iii-data-318438http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/gammagard-liquid-10-phase-iii-data-318438Clinical ResultsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/h5n1-vlp-vaccine-interim-phase-i-data-318452http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/h5n1-vlp-vaccine-interim-phase-i-data-318452Clinical ResultsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/lyme-disease-vaccine-phase-iii-data-318439http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/lyme-disease-vaccine-phase-iii-data-318439Clinical ResultsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/n-3-polyunsaturated-fatty-acids-phase-iii-data-318451http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/n-3-polyunsaturated-fatty-acids-phase-iii-data-318451Clinical ResultsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/prostate-cancer-index-diagnostic-data-318441http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/prostate-cancer-index-diagnostic-data-318441Clinical ResultsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/provenge-sipuleucel-t-phase-ii-data-318447http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/provenge-sipuleucel-t-phase-ii-data-318447Clinical ResultsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/prt064445-preliminary-phase-ii-data-318454http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/prt064445-preliminary-phase-ii-data-318454Clinical ResultsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/px-866-phase-ii-data-318453http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/px-866-phase-ii-data-318453Clinical ResultsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/single-dose-sufentanil-nanotab-phase-ii-data-318435http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/single-dose-sufentanil-nanotab-phase-ii-data-318435Clinical ResultsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/tamibarotene-phase-iib-discontinued-318446http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/tamibarotene-phase-iib-discontinued-318446Clinical ResultsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/tecfidera-dimethyl-fumarate-autoimmune-data-318440http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/tecfidera-dimethyl-fumarate-autoimmune-data-318440Clinical ResultsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/vectibix-panitumumab-phase-iii-data-318437http://www.biocentury.com/weekinreview/clinicalresults/2013-05-13/vectibix-panitumumab-phase-iii-data-318437Clinical ResultsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/preclinical/2013-05-13/royal-dsm-preclinical-data-318496http://www.biocentury.com/weekinreview/preclinical/2013-05-13/royal-dsm-preclinical-data-318496Preclinical ResultsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/aldoxorubicin-phase-iib-ongoing-318507http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/aldoxorubicin-phase-iib-ongoing-318507Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/ampion-phase-iii-ongoing-318500http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/ampion-phase-iii-ongoing-318500Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/androxal-enclomiphene-completed-phase-iii-enrollment-318526http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/androxal-enclomiphene-completed-phase-iii-enrollment-318526Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/avi-7288-phase-i-started-318528http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/avi-7288-phase-i-started-318528Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/avl-301-phase-iii-amended-318502http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/avl-301-phase-iii-amended-318502Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/bavituximab-completed-phase-i-enrollment-318523http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/bavituximab-completed-phase-i-enrollment-318523Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/blood-based-autism-test-clinical-trial-started-318530http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/blood-based-autism-test-clinical-trial-started-318530Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/cmx001-phase-iii-start-318504http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/cmx001-phase-iii-start-318504Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/cytovir-adv-phase-iii-started-318503http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/cytovir-adv-phase-iii-started-318503Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/elobixibat-phase-iii-started-318499http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/elobixibat-phase-iii-started-318499Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/emixustat-hydrochloride-phase-iibiii-started-318498http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/emixustat-hydrochloride-phase-iibiii-started-318498Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/enobosarm-phase-ii-started-318511http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/enobosarm-phase-ii-started-318511Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/ibrutinib-expanded-access-program-started-318524http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/ibrutinib-expanded-access-program-started-318524Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/imo-3100-development-discontinued-318512http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/imo-3100-development-discontinued-318512Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/imo-8400-phase-ii-start-318513http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/imo-8400-phase-ii-start-318513Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/inc280-phase-ii-started-318514http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/inc280-phase-ii-started-318514Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/ipi-145-phase-ii-started-318515http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/ipi-145-phase-ii-started-318515Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/isis-stat3rx-phase-ibiia-started-318516http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/isis-stat3rx-phase-ibiia-started-318516Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/iv-rigosertib-completed-phase-iii-enrollment-318521http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/iv-rigosertib-completed-phase-iii-enrollment-318521Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/laviv-azficel-t-phase-ii-started-318510http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/laviv-azficel-t-phase-ii-started-318510Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/lurbinectedin-completed-phase-ii-enrollment-318525http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/lurbinectedin-completed-phase-ii-enrollment-318525Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/mek162-phase-iii-start-318501http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/mek162-phase-iii-start-318501Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/mor208-phase-ii-started-318518http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/mor208-phase-ii-started-318518Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/nalbuphine-er-phase-i-started-318509http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/nalbuphine-er-phase-i-started-318509Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/nx-1207-completed-phase-iii-enrollment-318520http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/nx-1207-completed-phase-iii-enrollment-318520Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/ogx-427-phase-ii-started-318517http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/ogx-427-phase-ii-started-318517Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/opn-305-phase-ii-started-318522http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/opn-305-phase-ii-started-318522Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/proellex-telapristone-phase-ii-start-318527http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/proellex-telapristone-phase-ii-start-318527Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/rq-00000004-phase-ii-started-318505http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/rq-00000004-phase-ii-started-318505Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/selexipag-phase-iii-ongoing-318497http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/selexipag-phase-iii-ongoing-318497Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/tirasemtiv-phase-iib-expanded-318506http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/tirasemtiv-phase-iib-expanded-318506Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/tm-400-phase-iii-started-318531http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/tm-400-phase-iii-started-318531Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/tropicamide-phase-ii-started-318519http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/tropicamide-phase-ii-started-318519Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/tru-016-completed-phase-ibii-enrollment-318508http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/tru-016-completed-phase-ibii-enrollment-318508Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/vyvanse-lisdexamfetamine-dimesylate-development-discontinued-318529http://www.biocentury.com/weekinreview/clinicalstatus/2013-05-13/vyvanse-lisdexamfetamine-dimesylate-development-discontinued-318529Clinical StatusMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-cardio3-biosciences-completes-venture-financing-318532http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-cardio3-biosciences-completes-venture-financing-318532Completed OfferingsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-discovery-laboratories-completes-follow-on-318533http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-discovery-laboratories-completes-follow-on-318533Completed OfferingsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-idera-completes-follow-on-318534http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-idera-completes-follow-on-318534Completed OfferingsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-inflammatorx-completes-venture-financing-318535http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-inflammatorx-completes-venture-financing-318535Completed OfferingsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-isis-pharmaceuticals-completes-follow-on-318536http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-isis-pharmaceuticals-completes-follow-on-318536Completed OfferingsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-lumena-pharmaceuticals-completes-venture-financing-318537http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-lumena-pharmaceuticals-completes-venture-financing-318537Completed OfferingsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-neurophage-completes-venture-financing-318538http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-neurophage-completes-venture-financing-318538Completed OfferingsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-receptos-completes-ipo-318539http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-receptos-completes-ipo-318539Completed OfferingsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-silence-therapeutics-completes-placing-318540http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-silence-therapeutics-completes-placing-318540Completed OfferingsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-sirona-biochem-completes-debt-financing-318542http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-sirona-biochem-completes-debt-financing-318542Completed OfferingsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-sirona-biochem-completes-private-placement-of-units-318541http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-sirona-biochem-completes-private-placement-of-units-318541Completed OfferingsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-sqi-diagnostics-completes-private-placement-of-units-318543http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-sqi-diagnostics-completes-private-placement-of-units-318543Completed OfferingsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-stat-diagnostica-and-innovation-completes-venture-financing-318544http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-stat-diagnostica-and-innovation-completes-venture-financing-318544Completed OfferingsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-tacurion-completes-venture-financing-318545http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-tacurion-completes-venture-financing-318545Completed OfferingsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-trevena-completes-venture-financing-318546http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-trevena-completes-venture-financing-318546Completed OfferingsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-zalicus-completes-private-placement-318547http://www.biocentury.com/weekinreview/offerings/2013-05-13/completedofferings-zalicus-completes-private-placement-318547Completed OfferingsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/proposedofferings-ambit-proposes-private-placement-318585http://www.biocentury.com/weekinreview/offerings/2013-05-13/proposedofferings-ambit-proposes-private-placement-318585Proposed OfferingsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/proposedofferings-anges-proposes-private-placement-318586http://www.biocentury.com/weekinreview/offerings/2013-05-13/proposedofferings-anges-proposes-private-placement-318586Proposed OfferingsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/proposedofferings-heat-biologics-proposes-ipo-318587http://www.biocentury.com/weekinreview/offerings/2013-05-13/proposedofferings-heat-biologics-proposes-ipo-318587Proposed OfferingsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/proposedofferings-omeros-proposes-direct-public-offering-318588http://www.biocentury.com/weekinreview/offerings/2013-05-13/proposedofferings-omeros-proposes-direct-public-offering-318588Proposed OfferingsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/proposedofferings-peptidream-proposes-ipo-318589http://www.biocentury.com/weekinreview/offerings/2013-05-13/proposedofferings-peptidream-proposes-ipo-318589Proposed OfferingsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/proposedofferings-vermillion-proposes-private-placement-of-common-stock-and-warrants-318590http://www.biocentury.com/weekinreview/offerings/2013-05-13/proposedofferings-vermillion-proposes-private-placement-of-common-stock-and-warrants-318590Proposed OfferingsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/withdrawnofferings-harvard-apparatus-withdraws-ipo-318549http://www.biocentury.com/weekinreview/offerings/2013-05-13/withdrawnofferings-harvard-apparatus-withdraws-ipo-318549Withdrawn OfferingsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/amendedofferings-portola-amends-ipo-318548http://www.biocentury.com/weekinreview/offerings/2013-05-13/amendedofferings-portola-amends-ipo-318548Amended OfferingsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/otherfinancialnews-frazier-healthcare-financial-update-318550http://www.biocentury.com/weekinreview/offerings/2013-05-13/otherfinancialnews-frazier-healthcare-financial-update-318550Other Financial NewsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/otherfinancialnews-good-start-genetics-financial-update-318551http://www.biocentury.com/weekinreview/offerings/2013-05-13/otherfinancialnews-good-start-genetics-financial-update-318551Other Financial NewsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/otherfinancialnews-innovus-financial-update-318552http://www.biocentury.com/weekinreview/offerings/2013-05-13/otherfinancialnews-innovus-financial-update-318552Other Financial NewsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/otherfinancialnews-insys-financial-update-318553http://www.biocentury.com/weekinreview/offerings/2013-05-13/otherfinancialnews-insys-financial-update-318553Other Financial NewsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/otherfinancialnews-invivo-therapeutics-financial-update-318554http://www.biocentury.com/weekinreview/offerings/2013-05-13/otherfinancialnews-invivo-therapeutics-financial-update-318554Other Financial NewsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/otherfinancialnews-jazz-pharmaceuticals-financial-update-318555http://www.biocentury.com/weekinreview/offerings/2013-05-13/otherfinancialnews-jazz-pharmaceuticals-financial-update-318555Other Financial NewsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/otherfinancialnews-shire-financial-update-318556http://www.biocentury.com/weekinreview/offerings/2013-05-13/otherfinancialnews-shire-financial-update-318556Other Financial NewsMon, 13 May 2013 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2013-05-13/otherfinancialnews-supernus-financial-update-318557http://www.biocentury.com/weekinreview/offerings/2013-05-13/otherfinancialnews-supernus-financial-update-318557Other Financial NewsMon, 13 May 2013 00:00:00 -0700